Datapoint: FDA Approves Jemperli as Frontline Endometrial Cancer Treatment

The FDA on July 31 approved GSK’s Jemperli for the treatment of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer in adult patients who are also receiving chemotherapy. Notably, the drug beat out fellow PD-1 inhibitor Keytruda, which is still awaiting a first-line endometrial cancer decision from the FDA. Jemperli was first approved in April 2021 to treat dMMR recurrent or advanced endometrial cancer in patients that have already received platinum-based chemotherapy. It currently holds covered or better status for 88% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 8/2/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 8

Datapoint: GSK Scores Full Approval for Jemperli

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 21

Datapoint: Could Florida Be Poised to Expand Medicaid?

Read More
a-doctor-video-chatting
February 11

New York Medicaid Insurer Hopes Virtual Care Will Boost Access

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today